Moderna announces initial Phase 3 data showing its COVID-19 vaccine is up to 94.5% effective
In another promising medical development, the biotechnology company Moderna has announced its COVID-19 vaccine could be up to 94.5% effective.
The news comes a week after Pfizer announced its vaccine could be up to 90% effective based on a similar, early analysis from its Phase 3 trial.
In a release Monday, Moderna said its Phase 3 trial "met statistical criteria with a vaccine efficacy of 94.5%," according to an early analysis of the data that included 95 participants with confirmed cases of COVID-19.
However, vaccine specialists caution that these numbers are not set in stone -- both estimates could increase or decrease as the respective trials continue, and the vaccines may ultimately prove to work better in some groups than in others.
Despite the promising data, Moderna isn't ready to roll out its vaccine in a mass immunization campaign just yet. The company will first need to ask the Food and Drug Administration for emergency use authorization (EUA), a limited green-light for higher-risk groups.
The company said it plans to seek EUA "in the coming weeks." That application will include at least two months of safety data after the last injection in half the volunteers.
Moderna has said it expects the FDA application will include the "final analysis" of 151 cases of COVID-19 in its trial, rather than just the initial 95 cases.
This puts them roughly on track along with Pfizer for possible limited authorization by the FDA as soon as December. Moderna is expected to have 20 million doses to go along with Pfizer's 50 million for global distribution before more can be made in 2021.
Moderna also announced promising data Monday about how the vaccine can be shipped and stored. According to the company, the vaccine can safely be stored for up to six months in a normal freezer, and up to 30 days in a normal refrigerator.
Pfizer's vaccine must be kept at around -94 degrees Fahrenheit -- far colder than a typical freezer can accommodate. Because of these temperature requirements, the company will ship vaccine doses in special temperature-controlled thermal boxes packed with dry ice.
With the new data published this week, Moderna could be the second company to seek authorization in the United States, after Pfizer.
ABC News' Sony Salzman contributed to this report.